# NCT04676477 (NCT04676477)

> HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: patritumab deruxtecan plus osimertinib; patritumab deruxtecan
- Indication: locally advanced or metastatic EGFR-mutated NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04676477
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: HER3-DXd; HER3-DXd; Osimertinib; Osimertinib; HER3-DXd; HER3-DXd; Osimertinib
- Enrollment: 246
- Primary outcome: Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
- Primary outcome: Second-line Dose Expansion and First-line Dose Expansion: Objective Response Rate (ORR)

## Indexed commentary on NCT04676477 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04676477